Stock CRIS CURIS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Curis, Inc.

Equities

CRIS

US2312693094

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
14.85 USD +3.77% Intraday chart for Curis, Inc. +1.99% +16.47%
Feb. 09 HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating MT
Feb. 08 Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Curis Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Curis to Present at Upcoming Healthcare Conferences in April
PR
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
PR
HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating
MT
Curis Provides Fourth Quarter 2023 Business Update
AQ
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transcript : Curis, Inc., Q4 2023 Earnings Call, Feb 08, 2024
Curis: Q4 Earnings Snapshot
AQ
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M
MT
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
PR
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
PR
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study
CI
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
PR
Curis Enters into Agreement for Emavusertib, Pembrolizumab Combination Study in Melanoma
AQ
Curis Announces Three Presentations at ASH
PR
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
PR
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CRIS Stock
  4. News Curis, Inc.